Navigation Links
Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
Date:7/17/2009

SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, plans to announce the results of the three remaining Phase 3 clinical trials in the Contrave program on Monday, July 20, 2009 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time.

Orexigen management will host the call and webcast to discuss the results of these clinical trials and answer questions. The live call may be accessed by phone by calling 1-800-561-2813 (domestic) or 617-614-3529 (international), participant code 14007929. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase III clinical trials, and Empatic(TM) which is in the later stages of Phase II development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)...  CVS Pharmacy, the retail division of CVS ... design to enhance the retail customer experience with ... and expanded beauty selections paired with informational signage ... offerings. Together with its innovative digital programs, these ... experience at CVS Pharmacy.  "Pharmacy ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading provider ... care management module. Using this new feature, sleep physicians can now predict the ... continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea therapy. ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... instrument solutions, announces the continuation of its strategic partnership with and platinum sponsorship ... developing nations in the safe and effective management of complex spine deformity cases, ...
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored with the ... the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I ... improve the lives of the poor and underserved in other parts of the world,” ...
(Date:4/24/2017)... ... 24, 2017 , ... The bar for just about everything—apparel, eyewear, cars and ... air of pop and film stardom.(1) Not to be left out is that most ... now run the gamut from being encrusted with jewels and precious metals to, at ...
(Date:4/24/2017)... ... April 24, 2017 , ... Veteran Theresa James awoke to the sound ... forever. , In “Healing Tears,” James depicts every parent’s worst nightmare, when her three ... began journaling conversations and situations throughout my divorce,” James said. “After the death of ...
Breaking Medicine News(10 mins):